Table 1.
Global isoniazid (INH) resistance patterns given resistance to rifampin (RIF), by MDR-TB prevalence tertiles (% MDR-TB of those tested) based on WHO/IUTLD Global DRS data 1994–20071.
| MDR-TB prevalence cohort2, 3 | # of settings represented | Isolates with any resistance to RIF/total tested | Isolates resistant to RIF
|
||
|---|---|---|---|---|---|
| Susceptible to INH (% of any RIF resistance) | Resistant to INH (% of any RIF resistance) | ||||
|
| |||||
| n/N | % | n (%) | n (%) | ||
| New cases | |||||
| Low (<0.78%) | 45 | 374/47,744 | 0.8 | 162 (43.3) | 212 (56.7) |
| Medium (0.78–2.40%) | 47 | 1,566/87,806 | 1.8 | 382 (24.4) | 1,184 (75.6) |
| High (≥2.40%) | 46 | 3,363/46,107 | 7.3 | 472 (14.0) | 2,891 (86.0) |
| Total | 138 | 5,303/181,657 | 2.9 | 1,016 (19.2) | 4,287 (80.8) |
| Retreatment cases | |||||
| Low (<6.61%) | 42 | 462/7,662 | 6.0 | 111 (24.0) | 351 (76.0) |
| Medium (6.61–17.46%) | 44 | 1,642/13,283 | 12.4 | 205 (12.5) | 1,437 (87.5) |
| High (≥17.46%) | 43 | 6,308/15,393 | 41.0 | 534 (8.5) | 5,774 (91.5) |
| Total | 129 | 8,412/36,338 | 23.1 | 850 (10.1) | 7,562 (89.9) |
| Combined (new & retreatment) cases | |||||
| Low (<1.47%) | 41 | 1,432/100,004 | 1.4 | 365 (26.5) | 1,067 (73.5) |
| Medium (1.47–4.58%) | 43 | 1,852/59,854 | 3.1 | 337 (19.2) | 1,515 (80.8) |
| High (≥4.58%) | 41 | 9,278/61,226 | 15.2 | 913 (9.8) | 8,365 (90.2) |
| Total | 125 | 12,562/221,084 | 5.7 | 1,615 (12.9) | 10,947 (87.1) |
1
Global DRS report #5, 2008–2010, did not provide enough detail to be included in these data
2
Cohorts formed from country or subnational region data enumerated in the DRS data
3
For sites providing prevalence data in two or more years, the two more recent values were averaged